Policy of Prioritizing Retained Earnings and Growth Investment Over Dividends
First written in FY2017. 1 of 2 entries say "Restated". Latest entry: FY2023.
70 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「Accordingly, the Company will first secure retained earnings and work to eliminate the accumulated deficit at an early stage, while prioritizing the allocation of funds to capital expenditure and R&D investment aimed at obtaining manufacturing and marketing approval for regenerative medicine products, as well as capital expenditure and sales activities aimed at acquiring customers for the cell processing business.」
The Company continues to prioritize the elimination of the accumulated deficit and the allocation of funds to capital expenditure, R&D investment and customer acquisition activities while paying no dividends. - FY2017First statedAnnual report
「Our policy is first to secure retained earnings and work to eliminate accumulated losses at an early stage, while prioritizing the allocation of funds to capital investment and R&D investment required to obtain manufacturing and marketing approval for cell therapy products, as well as capital investment and sales activities to acquire customers for the cell-processing business. Through these measures, we will strengthen our corporate base and pursue business growth.」
The Company has paid no dividends since its establishment and intends for the time being to prioritize retained earnings and funding for capital investment, R&D investment and sales activities.